OAK RIDGE, Tenn., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the MedAxiom Cardiovascular (CV) Transforum Fall’25 Conference being held at the JW Marriott Austin, from Thursday, October 16 - Saturday, October 18 in Austin, TX. The CV Transforum is the leading conference for cardiovascular organizational performance solutions, uniting industry innovators and thought leaders from across th ...

Core Insights - Daxor Corporation's BVA technology significantly reduces hospital readmissions and improves survival rates in high-cost heart failure segments, validated by new clinical data presented at the HFSA Annual Scientific Meeting [1][3] - The newly FDA-cleared BVA analyzer is expected to capture a substantial share of the multi-billion-dollar market due to its enhanced ease of use, speed, and over 95% accuracy [2][3] Clinical Validation - Clinical findings indicate that patients optimally managed with BVA technology experienced zero unplanned readmissions, contrasting sharply with 57-77% for those with imbalances in blood volume [7] - The use of BVA-guided care in LVAD implantation resulted in improved outcomes, increasing 30-day survival from 90.3% to 93.6% and 1-year survival from 79.6% to 87.8%, while reducing 30-day readmissions from 28.6% to 18.5% [7] - Patients with Cardiac Amyloidosis showed significantly higher total blood and plasma volumes, indicating the diagnostic potential of BVA for accurate treatment [7] Company Overview - Daxor Corporation addresses the critical issue of accurately measuring blood volume, which is essential for optimal care in high-cost medical conditions like heart failure [4] - The company has 50 years of experience and operates a state-of-the-art manufacturing facility, positioning it for accelerated market expansion [4]

Core Insights - The study published in the Journal of Critical Care reveals frequent inaccuracies in clinical assessments of fluid status in critically ill patients, particularly those with sepsis and COVID-19 [1][2] - Daxor Corporation's BVA technology is highlighted as a solution to improve fluid management in critical care settings, emphasizing the need for accurate blood volume measurement [4][5] Study Findings - A significant percentage of patients were misclassified during clinical assessments, with 48% of COVID-19 patients incorrectly deemed hypervolemic when they were actually hypovolemic [8] - The study indicates that the albumin transudation rate (ATR) was persistently elevated in both sepsis and COVID-19 patients, suggesting ongoing capillary leakage [8] - Sepsis patients exhibited a higher ATR compared to COVID-19 patients, indicating more severe endothelial dysfunction despite lower admission severity scores [8] Company Positioning - Daxor's FDA-approved BVA-100™ Analyzer was utilized in the study, showcasing its capability to provide objective measurements of total blood volume and ATR [4] - The company has received FDA clearance for a new rapid BVA system, which is three times faster than the BVA-100™ and maintains over 95% accuracy, addressing urgent diagnostic needs in critical care [5][6] - Daxor is positioned for revenue expansion in critical care medicine, supported by new data, funding opportunities, and advancements in its technology [6][9]

Core Insights - Daxor Corporation is expanding its ezBVA Lab service into three regional healthcare facilities across the U.S., enhancing blood volume analysis capabilities and improving patient outcomes while reducing costs [2][3] - The ezBVA Lab provides comprehensive blood volume analysis results within 24 hours for both inpatient and outpatient settings, showcasing the efficiency and effectiveness of Daxor's technology [2][3] - Daxor's BVA technology has been integrated into various healthcare settings, including a prominent Midwest academic medical center and a leading cardiovascular institute in New Jersey, indicating its growing significance in modern healthcare [3][6] Company Overview - Daxor Corporation is recognized as the global leader in blood volume measurement technology, with its BVA-100® being the only FDA-cleared diagnostic blood test for quantifying blood volume status [4] - Over 65,000 tests have been performed at leading hospital centers across the U.S., significantly reducing mortality and readmissions in heart failure and critical care [4] - Daxor is involved in ongoing trials for heart failure treatment supported by the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [4]